6 years ago

Emergex Vaccines Raises Over US$11M in Series A Funding

  • Emergex Vaccines Holding Limited, a UK-based biotechnology company developing set-point vaccines to prevent serious infectious diseases, has secured over US$11m in Series A funding led by Vickers Venture Partners

  • The funds will be used to progress the company's development pipeline, including a first-in-man Phase 1 clinical trial of its Flavivirus (Dengue) vaccine in Switzerland, as well as Phase 1b clinical trials in Singapore and Brazil

  • Emergex focuses on developing vaccines that prevent virulent diseases such as Zika, Dengue Fever, Ebola and even pandemic Flu

  • The company's set-point vaccines deliver experimentally-derived pathogen peptide data via quantum-sized nanoclusters to prime the immune system to recognise subsequent infections, mimicking natural infection and preventing severe manifestation of the disease.

      • Problemlife sciences

      "preventing serious infectious diseases such as Zika, Dengue Fever, Ebola and even pandemic Flu"

      Solution

      "developing set-point vaccines that deliver experimentally-derived pathogen peptide data via quantum-sized nanoclusters to prime the immune system"

      Covered on